Gene test may predict who needs more immunotherapy after lung cancer surgery

NCT ID NCT07179445

Not yet recruiting Knowledge-focused Sponsor: Tianjin Medical University Cancer Institute and Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study looks at 300 lung cancer patients who had immunotherapy before surgery but still had cancer cells left after the operation. Researchers will use advanced gene testing to find hidden genetic changes that might explain why the cancer didn't fully disappear. The goal is to see if these genetic differences can help doctors decide who needs more treatment after surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help doctors identify which lung cancer patients might benefit from additional immunotherapy after surgery, leading to more personalized treatment plans.
What could go wrong: This is an observational study that only looks back at past data, so it cannot prove cause and effect. Results may not apply to all patients or lead to immediate changes in care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung adenocarcinoma non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NSCLC

Contacts and locations

Locations

Tianjin Medical University Cancer Institute and Hospital(Lead Center)

Tianjin, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.